Rhythm Pharmaceuticals, Inc. (RYTM) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
45.14
↑+140% vs avg
5yr avg: 18.77
30Y Low1.7·High50.0
ROE
↓
-129.5%
↑-38% vs avg
5yr avg: -93.5%
30Y Low-156%·High-31%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RYTM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rhythm Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.6B | $7.0B | $3.4B | $2.7B | $1.5B | $495M | $1.3B | $836M | $833M | $777M | — |
| Enterprise Value | $6.8B | $7.1B | $3.3B | $2.6B | $1.4B | $438M | $1.2B | $778M | $784M | $743M | — |
| P/E Ratio → | -31.06 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 34.77 | 36.66 | 26.24 | 34.24 | 64.21 | 156.95 | — | — | — | — | — |
| P/B Ratio | 45.14 | 50.02 | 20.75 | 15.62 | 5.74 | 1.74 | 7.88 | 2.98 | 3.38 | 5.36 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RYTM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 37.67 | 25.59 | 33.48 | 58.89 | 138.97 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
RYTM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Rhythm Pharmaceuticals, Inc. earns an operating margin of -101.2%. Operating margins have expanded from -238.1% to -101.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -129.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.7% | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% | — | — | — | — | — |
| Operating Margin | -101.2% | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% | — | — | — | — | — |
| Net Profit Margin | -103.6% | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -129.5% | -129.5% | -155.9% | -85.1% | -66.1% | -30.9% | -58.4% | -51.1% | -37.9% | -44.3% | -131.7% |
| ROA | -45.0% | -45.0% | -71.9% | -51.6% | -50.9% | -27.0% | -52.8% | -47.3% | -36.0% | -41.1% | -104.3% |
| ROIC | -70.1% | -70.1% | -209.3% | -110.9% | -73.4% | -86.1% | -70.4% | -52.3% | -38.3% | -43.7% | — |
| ROCE | -58.9% | -58.9% | -95.8% | -59.4% | -57.0% | -74.7% | -60.3% | -55.0% | -40.0% | -42.5% | -130.8% |
RYTM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $192M ($246M total debt minus $54M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.77 | 1.77 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.38 | -0.52 | -0.35 | -0.48 | -0.20 | -0.59 | -0.21 | -0.20 | -0.24 | -0.90 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.52 | -8.52 | -11.63 | -12.25 | -33.82 | — | — | — | — | — | — |
RYTM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Rhythm Pharmaceuticals, Inc.'s current ratio of 4.41x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.58x to 4.41x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.41 | 4.41 | 3.24 | 5.58 | 8.90 | 7.10 | 10.10 | 12.38 | 19.05 | 22.42 | 2.36 |
| Quick Ratio | 4.16 | 4.16 | 3.08 | 5.43 | 8.83 | 7.10 | 10.10 | 12.38 | 19.05 | 22.42 | 2.36 |
| Cash Ratio | 3.67 | 3.67 | 2.78 | 5.00 | 8.37 | 6.79 | 9.60 | 11.98 | 18.56 | 22.04 | 2.23 |
| Asset Turnover | — | 0.39 | 0.33 | 0.23 | 0.06 | 0.01 | — | — | — | — | — |
| Inventory Turnover | 0.76 | 0.76 | 0.71 | 1.08 | 0.73 | 5.40 | — | — | — | — | — |
| Days Sales Outstanding | — | 50.17 | 51.93 | 70.08 | 96.11 | 118.62 | — | — | — | — | — |
RYTM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rhythm Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $65M | $61M | $58M | $52M | $50M | $44M | $36M | $31M | $27M | $17M |
Peer Comparison
Compare RYTM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RYTMYou | $7B | -31.1 | — | — | 89.7% | -101.2% | -129.5% | -70.1% | — |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 ACMR | $4B | 40.4 | 25.5 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
 KRYS | $9B | 42.2 | 47.8 | 45.1 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 VNDA | $440M | -2.0 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 MDGL | $12B | -42.0 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 VKTX | $4B | -10.1 | — | — | — | — | -47.3% | -44.4% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See RYTM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RYTM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RYTM vs HALO
Side-by-side business, growth, and profitability comparison vs Halozyme Therapeutics, Inc..
Start ComparisonRYTM — Frequently Asked Questions
Quick answers to the most common questions about buying RYTM stock.
What is Rhythm Pharmaceuticals, Inc.'s P/E ratio?
Rhythm Pharmaceuticals, Inc.'s current P/E ratio is -31.1x. This places it at the 50th percentile of its historical range.
What is Rhythm Pharmaceuticals, Inc.'s ROE?
Rhythm Pharmaceuticals, Inc.'s return on equity (ROE) is -129.5%. The historical average is -78.3%.
Is RYTM stock overvalued?
Based on historical data, Rhythm Pharmaceuticals, Inc. is trading at a P/E of -31.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Rhythm Pharmaceuticals, Inc.'s profit margins?
Rhythm Pharmaceuticals, Inc. has 89.7% gross margin and -101.2% operating margin.